INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13301, 30190, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13302, 30191, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13303, 32234, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13304, 32301, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13305, 32302, 'Olanzapine', 'Phenylketonurias', 'Zyprexa Zydis (brand of olanzapine orally distintegrating tablets) contains 0.34 mg and 0.45 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively.  The phenylalanine content should be considered when this and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13306, 0, 'Oliceridine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13307, 0, 'Oliceridine', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13308, 0, 'Oliceridine', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13309, 0, 'Oliceridine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13310, 0, 'Oliceridine', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13311, 0, 'Oliceridine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13312, 0, 'Oliceridine', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13313, 0, 'Oliceridine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13314, 0, 'Oliceridine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13315, 0, 'Oliceridine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13316, 0, 'Omadacycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13317, 22141, 'Olaparib', 'Neutropenia', 'Olaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes.  Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia.  Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1).  It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment.  Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13318, 22142, 'Olaparib', 'Neutropenia', 'Olaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes.  Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia.  Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1).  It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment.  Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13319, 22141, 'Olaparib', 'Hepatic Insufficiency', 'Olaparib primarily undergoes hepatic metabolism via CYP450 3A4 and CYP450 3A5; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation.  No dose adjustment is needed in patients with mild hepatic impairment.  It is recommended to use caution when using olaparib in patients with moderate or severe hepatic impairment as there are no data available.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13320, 22142, 'Olaparib', 'Hepatic Insufficiency', 'Olaparib primarily undergoes hepatic metabolism via CYP450 3A4 and CYP450 3A5; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation.  No dose adjustment is needed in patients with mild hepatic impairment.  It is recommended to use caution when using olaparib in patients with moderate or severe hepatic impairment as there are no data available.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13321, 22141, 'Olaparib', 'Respiration Disorders', 'Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib.  It is recommended to interrupt treatment if patients present new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality.  Assess for the source of symptoms and if pneumonitis is confirmed, olaparib should be discontinued and the patient treated appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13322, 22142, 'Olaparib', 'Respiration Disorders', 'Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib.  It is recommended to interrupt treatment if patients present new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality.  Assess for the source of symptoms and if pneumonitis is confirmed, olaparib should be discontinued and the patient treated appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13323, 22141, 'Olaparib', 'Kidney Diseases', 'In a olaparib renal impairment trial, the mean AUC increased by 24%, and the Cmax increased by 15%, in patients with mild renal impairment.  In patients with moderate renal impairment, the AUC increased by 44% and the Cmax by 26%.  No dose adjustment is needed in patients with mild renal impairment.  The dose of olaparib in patients with moderate renal impairment should be adjusted according to the prescribing information.  It is recommended to monitor for toxicity all patient with renal impairment.  The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13324, 22142, 'Olaparib', 'Kidney Diseases', 'In a olaparib renal impairment trial, the mean AUC increased by 24%, and the Cmax increased by 15%, in patients with mild renal impairment.  In patients with moderate renal impairment, the AUC increased by 44% and the Cmax by 26%.  No dose adjustment is needed in patients with mild renal impairment.  The dose of olaparib in patients with moderate renal impairment should be adjusted according to the prescribing information.  It is recommended to monitor for toxicity all patient with renal impairment.  The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13325, 1166, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13326, 1957, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13327, 3311, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13328, 3314, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13329, 4122, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13330, 4123, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13331, 4363, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13332, 4533, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13333, 4536, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13334, 4691, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13335, 5233, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13336, 6398, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13337, 6923, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13338, 10313, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13339, 12911, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13340, 12912, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13341, 12913, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13342, 12914, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13343, 14667, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13344, 17090, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13345, 17091, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13346, 17095, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13347, 17096, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13348, 17097, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13349, 17098, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13350, 18232, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13351, 18233, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13352, 24111, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13353, 24112, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13354, 24113, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13355, 24114, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13356, 24115, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13357, 29991, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13358, 29992, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13359, 32150, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13360, 32170, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13361, 32703, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13362, 32704, 'Ondansetron', 'Long QT Syndrome', 'ECG changes including QT interval prolongation have been observed in patients receiving ondansetron.  Additionally, there have been some postmarketing reports of Torsade de Pointes cases.  The use of ondansetron should be avoided in patients with congenital long QT syndrome.  ECG monitoring is recommended in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, patients with congestive heart failure, bradyarrhythmias, or patients taking other medicines that could lead to QT prolongation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13363, 1166, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13364, 1957, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13365, 3311, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13366, 3314, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13367, 4122, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13368, 4123, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13369, 4363, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13370, 4533, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13371, 4536, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13372, 4691, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13373, 5233, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13374, 6398, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13375, 6923, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13376, 10313, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13377, 12911, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13378, 12912, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13379, 12913, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13380, 12914, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13381, 14667, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13382, 17090, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13383, 17091, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13384, 17095, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13385, 17096, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13386, 17097, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13387, 17098, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13388, 18232, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13389, 18233, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13390, 24111, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13391, 24112, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13392, 24113, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13393, 24114, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13394, 24115, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13395, 29991, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13396, 29992, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13397, 32150, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13398, 32170, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13399, 32703, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (13400, 32704, 'Ondansetron', 'Liver Diseases', 'Ondansetron is extensively metabolized by the liver.  The plasma clearance of ondansetron may be substantially decreased and the half-life prolonged in patients with impaired hepatic function.  During clinical trials in patients receiving concomitant chemotherapy, transient elevations of serum transaminases and isolated cases of jaundice have been reported.  Therapy with ondansetron should be administered cautiously at reduced dosages in patients with liver disease.  The manufacturer recommends a maximum daily dosage of 8 mg in severe hepatic impairment.', '2', '', 'DDInter', 0);
